Skip to Content
Merck
CN
  • Potent antagonism by BIM-23056 at the human recombinant somatostatin sst5 receptor.

Potent antagonism by BIM-23056 at the human recombinant somatostatin sst5 receptor.

British journal of pharmacology (1996-06-01)
G F Wilkinson, R J Thurlow, L A Sellers, J E Coote, W Feniuk, P P Humphrey
ABSTRACT

We have investigated the effects of somatostatin (SRIF) and the linear octapeptide BIM-23056 on changes in intracellular calcium ion concentration ([Ca2+]i) and on the formation of inositol-1,4,5-trisphosphate (Ins(1,4,5)P3) in CHO-K1 cells transfected with the human recombinant SRIF sst5 receptor. SRIF elicited concentration-dependent increases in [Ca2+]i, with a pEC50 of 7.02 +/- 0.06, while BIM-23056 (1 x 10(-7) M) behaved not as an agonist but as a potent, surmountable antagonist of these increases in [Ca2+]i. The SRIF concentration-effect curve for increases in [Ca2+]i was shifted rightward producing an estimated pKB for the antagonist of 8.0. BIM-23056 (1 x 10(-7) M) also significantly attenuated Ins(1,4,5)P3 increases due to SRIF, but had no effect on either basal or uridine 5'-triphosphate (UTP) (1 x 10(-4) M) stimulated increases in the levels of [Ca2+]i or Ins(1,4,5)P3.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
BIM 23056, ≥95% (HPLC), solid